Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC

Vasko Kramer, René Fernández, Wencke Lehnert, Luis D. Jiménez-Franco, Cristian Soza-Ried, Elisabeth Eppard, Matias Ceballos, Marian Meckel, Martina Benešová, Christoph A. Umbricht, Andreas Kluge, Roger Schibli, Konstantin Zhernosekov, Horacio Amaral & Cristina Müller
Introduction PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to increase the tumor uptake in preclinical experiments. The aim of this study was to translate the concept to a clinical setting and evaluate the safety and dosimetry of [177Lu]Lu-PSMA-ALB-56, a novel PSMA radioligand with albumin-binding properties. Methods Ten...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.